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Abstract
A major challenge in developing vaccines for emerging pathogens is their continued evolution and ability to escape human
immunity. Therefore, an important goal of vaccine research is to advance vaccine candidates with sufficient breadth to
respond to new outbreaks of previously undetected viruses. Ebolavirus (EBOV) vaccines have demonstrated protection
against EBOV infection in nonhuman primates (NHP) and show promise in human clinical trials but immune protection
occurs only with vaccines whose antigens are matched to the infectious challenge species. A 2007 hemorrhagic fever
outbreak in Uganda demonstrated the existence of a new EBOV species, Bundibugyo (BEBOV), that differed from viruses
covered by current vaccine candidates by up to 43% in genome sequence. To address the question of whether cross-
protective immunity can be generated against this novel species, cynomolgus macaques were immunized with DNA/rAd5
vaccines expressing ZEBOV and SEBOV glycoprotein (GP) prior to lethal challenge with BEBOV. Vaccinated subjects
developed robust, antigen-specific humoral and cellular immune responses against the GP from ZEBOV as well as cellular
immunity against BEBOV GP, and immunized macaques were uniformly protected against lethal challenge with BEBOV. This
report provides the first demonstration of vaccine-induced protective immunity against challenge with a heterologous
EBOV species, and shows that Ebola vaccines capable of eliciting potent cellular immunity may provide the best strategy for
eliciting cross-protection against newly emerging heterologous EBOV species.
Citation: Hensley LE, Mulangu S, Asiedu C, Johnson J, Honko AN, et al. (2010) Demonstration of Cross-Protective Vaccine Immunity against an Emerging
Pathogenic Ebolavirus Species. PLoS Pathog 6(5): e1000904. doi:10.1371/journal.ppat.1000904
Editor: Christopher F. Basler, Mount Sinai School of Medicine, United States of America
Received December 10, 2009; Accepted April 9, 2010; Published May 20, 2010
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported in part by the Intramural Research Program of the Vaccine Research Center, NIAID, National Institutes of Health. The funders
had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: NJS and PBJ are named on patent applications for Ebola vaccines.
* E-mail: nsullivan@nih.gov
. These authors contributed equally to this work.
¤ Current address: University of Texas Medical Branch, Galveston National Laboratory, Galveston, Texas, United States of America
Introduction
The Ebolavirus genus of the family Filoviridae was thought
previously to consist of four species, ZEBOV, SEBOV, Reston
(REBOV), and Cote d’Ivoire (CIEBOV) [1]. Of these, ZEBOV
and SEBOV have been associated with the majority of Ebola virus
hemorrhagic fever (EHF) cases in humans [2]. Within the last
decade, the frequency of EBOV outbreaks in Africa has increased,
probably due to human encroachment on the natural habitat of
animal reservoir(s) and/or improved surveillance [3]. Due to the
aggressive nature of EHF symptoms, the rapid spread of infection
to other persons in close contact with the infected individual,
resultant high mortality rate and threat of bioterrorism, vaccine
development against EBOV virus is a high priority. EHF vaccines
based on recombinant adenovirus serotype 5 (rAd5) vectors
encoding the ZEBOV and SEBOV envelope glycoproteins, GP(Z)
and GP(S/G), respectively, have shown protective efficacy in NHP
[4,5,6] and hold promise as vaccine candidates for human use [7].
In addition to rAd vaccines, other viral-vectored and virus-like
particle (VLP) vaccines have exhibited protective efficacy against
EBOV infection in NHP [8,9,10]. Though each of these vaccines
generates potent immune responses in NHP, protection is
achieved only when the vaccine immunogen and the EBOV
species used for infectious challenge are matched, and data show a
lack of cross protection against antigens not contained in the
vaccine [8], suggesting that existing vaccines may not provide
coverage against newly emerging EBOV species.
An outbreak of HF in Western Uganda in late 2007 led to the
identification of a fifth species in the genus Ebolavirus [11].
Complete genome sequence comparison of all EBOV species
revealed that the virus from Western Uganda, the Bundibugyo
species, differed from the previously characterized four EBOV
species by 32–42%, as is characteristic for divergence between
other members in the genus. Current human vaccine candidates
encode GP from SEBOV and ZEBOV, whose sequences differ
from BEBOV by 38–47% at the amino acid level. The lack of
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with sequence divergence in the same range suggests that vaccines
currently in development will not protect against emerging Ebola
viruses. We have shown previously that a prime-boost vaccine
strategy priming with DNA vectors and using rAd vectors to
provide the boost generates broad immune responses across both
T- and B-cell immune compartments [6]. This immunization
regimen has been demonstrated to generate antigen-specific
immune responses at least one log higher than those observed
with either DNA or rAd alone [12]. Therefore, we hypothesized
that a DNA prime/rAd5 EBOV vaccine strategy would be the
most likely candidate to induce cross-protection against BEBOV.
We demonstrate herein that potent responses induced by prime-
boost vaccination can provide immune protection against newly
emerging EBOV species and show for the first time vaccine-
induced species cross-protection against EBOV infection.
Results
Immunization of cynomolgus macaques with DNA/rAd
It has been demonstrated previously that NHP immunized with
a vaccine consisting of EBOV GP DNA followed by boosting with
rAd5 GP were uniformly protected when challenged with a lethal
dose of wild-type ZEBOV, Mayinga strain [6]. Four cynomolgus
macaques were injected at 4–6 week intervals with GP(Z) and
GP(S/G) DNA, followed by a rest period, and boosted after one
year with rAd5 vectors containing the EBOV matched insert
according to the schedule depicted in Figure 1A. Although
sequence divergence between genes coding for BEBOV GP and
the inserts contained within the previously used vaccine is
substantial, homology is displayed within the N- and C-terminal
regions of GP that contain structural elements critical for virus
replication [13]. This genetic relatedness between species was the
basis for selection of vaccine inserts with the goal of broad
coverage against multiple species. Phylogenetic analysis demon-
strates that ZEBOV shares genetic ancestry with CIEBOV and
BEBOV, while SEBOV is closest to REBOV (Figure 1B). To
assess whether ZEBOV and SEBOV gene inserts were likely to
provide cross protection against heterologous infectious challenge
with BEBOV, GP antigen-specific immune responses in humoral
and T cell compartments were assessed by ELISA and
intracellular cytokine staining (ICS), respectively, three weeks
after delivery of the rAd5-GP(Z) boost immunization.
Humoral immune responses elicited by prime-boost
immunization
Studies performed previously have shown an absence of
neutralizing antibody in vaccinated macaques and a lack of
correlation with protection from infection [14,15]. In contrast,
there is a strong association between GP-specific ELISA IgG titers
in serum or plasma of immunized animals and protection from
EBOV infection in NHP [6], and subsequent analysis has
illustrated that vaccine-induced ELISA titers correlate with
protection by rAd5 based vaccines [16]. Therefore, to assess
DNA/rAd vaccine immunogenicity in the current study, anti-GP
ELISA IgG responses specific for the ZEBOV vaccine insert were
measured at the end of the rest period following DNA
immunization (pre-boost) and compared to ELISA IgG titers after
boosting with rAd5-GP (post-boost)(Figure 2A). DNA priming
alone induced modest plasma antibody titers, averaging an
effective concentration (EC90) of 1/900 for all subjects in the
vaccine group. Subsequent immunization with rAd5-GP boosted
plasma titers by at least an order of magnitude in all subjects
(p=0.02, pre-boost vs. post-boost titers) and by two logs in subject
V2. These data confirm the potency of the prime boost vaccine
regimen and demonstrate that significant boosting of DNA-primed
humoral immunity can be achieved even one year after the final
priming immunization.
As an initial assessment of potential vaccine-induced cross-
species immunity against BEBOV, subject plasma samples were
evaluated using the same ELISA format described above except
the capture antigen used was BEBOV GP. Comparison of subject
antibody responses against BEBOV and ZEBOV (Figure 2B)
shows that the ZEBOV DNA/rAd vaccine did not generate
antibodies cross-reactive with BEBOV GP. Anti-BEBOV reactiv-
ity for all four vaccine subjects overlapped the average background
level of antigen binding displayed by samples from unvaccinated
control subjects (n=4). The absence of cross-specific antibody
reactivity suggests that immunoglobulins elicited by the DNA/rAd
vaccine were directed against linear amino acid sequences not
contained within BEBOV GP or against conformational epitopes
dependent on protein tertiary structure.
Vaccine induction of cross-reactive CD4
+ and CD8
+ T cells
In earlier work, DNA/rAd5 vaccine-induced EBOV cellular
immunity was assessed by measuring in vitro antigen-activated cell
proliferation in PBMC obtained from immunized subjects. While
proliferation assays provide a useful measure of T-cell immunity,
important effector cell activity, especially within the CD8 T-cell
compartment, may not be captured in these measurements [17].
Therefore, we evaluated PBMC from immunized macaques using
intracellular cytokine staining to assess memory and effector CD4
+
and CD8
+ T-cell functions. PBMC samples collected from
vaccinated animals four weeks after the rAd5 GP vaccine boost
were isolated by density gradient centrifugation and stimulated
with peptides spanning the ZEBOV or BEBOV GP reading
frame. Intracellular expression of TNFa, IFNc, and IL-2 induced
in the CD8
+ and CD4
+ memory T cell subsets was evaluated in
PBMC samples and quantified after gating on CD95 and
CD45RA memory markers (Figure 3A). DNA/rAd prime-boost
EBOV immunization generated antigen-specific CD4
+ T cell
immunity against proteins expressed by the vaccine insert
Author Summary
Ebola virus causes death, fear, and economic disruption
during outbreaks. It is a concern worldwide as a natural
pathogen and a bioterrorism agent, and has caused death
to residents and tourists of Africa where the virus
circulates. A vaccine strategy to protect against all
circulating Ebola viruses is complicated by the fact that
there are five different virus species, and individual
vaccines provide protection only against those included
in the vaccine. Making broad vaccines that contain
multiple components is complicated, expensive, and poses
challenges for regulatory approval. Therefore, in the
present work, we examined whether a prime-boost
immunization strategy with a vaccine targeted to one
Ebola virus species could cross protect against a different
species. We found that genetic immunization with vectors
expressing the Ebola virus glycoprotein from Zaire blocked
infection with a newly emerged virus species, Bundibugyo
EBOV, not represented in the vaccine. Protection occurred
in the absence of antibodies against the second species
and was mediated instead by cellular immune responses.
Therefore, single-component vaccines may be improved to
protect against multiple Ebola viruses if they are designed
to generate this type of immunity.
Vaccine-Induced Cross Protection for Ebolavirus
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+ T cells was
uniform across the four immunized macaques and exceeded that
observed with a single-shot rAd vaccine [5,12,18,19,20,21],
demonstrating the potency of DNA priming for augmentation of
CD4
+ T cell immunity seen by others [18]. In contrast to the
species specificity demonstrated for antibody responses in this
study, CD4
+ T cells elicited by the vaccine gene inserts were cross-
reactive with BEBOV GP. Intracellular cytokine secretion was
stimulated by BEBOV GP in each of the vaccinated macaques,
suggesting that dominant T-cell epitopes are contained within the
Figure 1. Vaccination and challenge schedule. (A) Vaccine group NHP were injected with plasmid DNA and rAd5 vectors encoding GP from
SEBOV and/or ZEBOV. Individual DNA immunizations were spaced by 4–6 week intervals and the rAd boost was given one year after the final DNA
prime. Animals were exposed to a lethal dose of BEBOV 7 weeks after the rAd5 GP boost. (B) Distance matrix-based phylogenetic tree for EBOV GP.
Numbers at the nodes are boostrap percentages. Vertical branches are for graphic representation; horizontal branch lengths are measured as
substitutions per site (scale bar =0.07). The infectious challenge species is shown in blue. Vaccine strains are indicated in bold.
doi:10.1371/journal.ppat.1000904.g001
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residues) for MHC class II presentation and TCR recognition.
Overall, the composite cellular immune response elicited by the
prime-boost immunization was skewed toward CD8
+ T cell
activity (Figure 3C). For ZEBOV, GP activation of CD8
+ T cells
was several fold higher (p=.05) than the corresponding CD4
+ T
cell responses as a percentage of the lineage memory population.
Subject A01088 was a notable outlier whose CD8
+ T responses
were markedly lower than in other subjects. As observed for CD4-
based immunity, CD8
+ memory cell cytokine responses were
higher than those obtained with a rAd-only vaccine, and the
results showed overall that prime-boost immunization with DNA/
rAd5 elicited potent antigen-specific humoral and cellular
immunity. Examination of the proportions of single-, double-,
and triple-positive cytokine producing cells did not reveal a
dominant phenotype among the vaccinated subjects. However, the
distribution of responses represented by each cytokine revealed
that IL-2 positive cells were a minor component of the overall
CD8
+ T-cell responses, but contributed a greater proportion of the
overall CD4+ T cell response as expected for this population
which must be fit to undergo proliferation in response to pathogen
exposure.
Infectious challenge of NHP with Bundibugyo EBOV
DNA/rAd5 immunization of cynomolgus macaques protects
against infection when animals are challenged with a virus species
homologous to the vaccine inserts. Although there was no
serological cross-reactivity between ZEBOV and BEBOV species,
sequence alignment demonstrated several regions of sequence
identity sufficient to comprise conserved CD4
+ and CD8
+ T-cell
epitopes (not shown), and immunized macaques exhibited robust
cellular immunity against the GP from both species. To test
whether immunity was sufficiently conserved to provide protection
against heterologous virus infection, ZEBOV-immunized animals
were challenged with a lethal dose (1000 TCID50) of BEBOV.
Infection was monitored using traditional measures of filovirus
infection including the appearance of maculopapular rash and
damage to hepatocytes [22]. The effect of infection on hepatocytes
was evaluated by measuring the liver enzymes AST and ALT. By
day 10 post-infection, all control subjects exhibited severe
Figure 2. Development of vaccine-induced antibody responses. (A) The quantity of anti-Ebola GP IgG in plasma samples from vaccinated
cynomolgus macaques was determined by ELISA as described in Methods. Results are shown for samples obtained after the final DNA prime and prior to
immunization withrAd (pre-boost,light blue), and for samples obtained 3 weeks after boostingwith rAd-GP (post-boost,dark blue). Plasma antibody titers
are presented as EC90 reciprocal dilution titers. (B) ELISA IgG against ZEBOV (blue) and BEBOV (red) antigens. Plasma dilution series are shown for each
immunized subject. The averages for negative control samples (n=4) are shown for ZEBOV (black dotted line) and BEBOV (black dashed line).
doi:10.1371/journal.ppat.1000904.g002
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viral RNA (Figure 4), characteristic of filovirus infection in
macaques. In the case of control subject C1, AST and ALT
subsequently decreased to normal and near normal levels,
respectively (Figure 4A,B). Three out of the four control animals
succumbed to infection with BEBOV between days 12 and 13
(Figure 4D). One unvaccinated control animal (C3) survived
challenge but exhibited the full constellation of EHF symptoms,
suggesting that this animal was infected but successfully cleared the
infection. The time course for lethal infection of control animals
was somewhat longer than a comparative infectious challenge with
ZEBOV which causes death in cynomolgus macaques on average
within one week following challenge [23]. Among the vaccinated
animals, AST levels remained normal or near normal at all tested
time points (Figure 4B). Subject V4 exhibited a mild, transient
increase in the serum levels of ALT, which was lower in magnitude
than that observed in the control animals. Additionally, viral RNA
was detected in this subject on day 6 post infection and returned to
undetectable levels by the next blood draw on day 10 (Figure 4C).
Thus, the four macaques that received the DNA prime/rAd5 GP
boost vaccine regimen generated immunity sufficient to prevent or
control BEBOV infection (p=0.04 vs. controls). These data
demonstrate that a DNA/rAd5 vaccine containing ZEBOV and
SEBOV antigens provides cross-protective immunity against
heterologous challenge with BEBOV.
Discussion
Until recently, there were four known species of EBOV, with
the most virulent being the ZEBOV and SEBOV species [24,25].
While there is evidence pointing to fruit bats as a possible natural
reservoir for EBOV, this has not yet been definitively proven.
Therefore, it is difficult to successfully implement public health
measures to prevent EHF outbreaks, and the potential use of
EBOV as a weapon of bioterrorism also necessitates the
development of medical countermeasures to prevent and/or treat
infection. The absence of effective therapies to mitigate EHF
symptoms and mortality reinforces the urgent need to develop an
effective vaccine against EBOV. Prior studies [5,6] demonstrated
that rAd or DNA/rAd genetic vaccines against ZEBOV provide
protection against challenge with an otherwise lethal dose of the
homologous virus species. Towner, et al., described a fifth Ebola
species in 2008, BEBOV, which was responsible for a hemorrhagic
fever outbreak in Uganda with a case fatality rate of approximately
36% [11]. The Bundibugyo species has 63%, 58% and 68%
sequence similarity to ZEBOV, SEBOV and CIEBOV species,
respectively, and there is little serological cross reactivity between
most species [26]. Since all vaccines shown to protect NHP are
targeted to ZEBOV and SEBOV, it is important to determine
whether new species should be incorporated as additional
components of vaccine formulations against EBOV or if current
vaccines may provide adequate coverage against emerging viruses
such as BEBOV.
The data presented here demonstrate that a vaccination
strategy targeting structural proteins from ZEBOV and SEBOV
was able to provide cross-protective immunity against infectious
challenge with a heterologous EBOV species. This may have been
due in part to the ability of DNA/rAd prime-boost vaccination to
generate more robust immune responses than single-shot vaccines.
The time to death for the BEBOV controls (12–14 days) was
Figure 3. T-cell immune responses measured by intracellular
cytokine staining. PBMC were stimulated with overlapping
peptides spanning the GP protein, and antigen-specific CD4
+ and
CD8
+ cells were enumerated in the memory cell gates (A) by the
detection of cytokine production. The percentages of cytokine-
positive CD4
+ (panel B) and CD8
+ (panel C) T cell memory cells
specific for ZEBOV (blue) and BEBOV (red) were determined at 4
weeks post rAd-GP boost. Responses are shown for each individual
cytokine measured as the total proportion of cells positive for TNFa
(blue), IFNc (gray), IL-2 (red), expressed as a percentage of the
memory cell population after background subtraction of control,
unstimulated, samples run in parallel.
doi:10.1371/journal.ppat.1000904.g003
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PLoS Pathogens | www.plospathogens.org 5 May 2010 | Volume 6 | Issue 5 | e1000904Figure 4. Bundibugyo EBOV challenge. Control and vaccinated animals were exposed to a target dose of ,1,000 TCID50 of BEBOV. Blood
samples were collected before and after infection for the determination of hepatic enzyme levels. ALT (panel A) and AST (panel B) were measured
using a General chemistry 12 reagent disk for the Piccolo Analyzer (Abaxis). Viral load (panel C) was determined by quantitative RT-PCR of plasma
Vaccine-Induced Cross Protection for Ebolavirus
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days) [5] suggesting it may also be possible that BEBOV is less
pathogenic than other EBOV species and therefore inherently
more sensitive to host immunity.
The observed 100% protection against BEBOV infection in
NHP would not be predicted given the divergence in GP sequence
between BEBOV GP and the vaccine inserts but suggests that
sufficient conservation of immunogenic regions exists between the
different species. Immunization with rAd-GP one year after the
final DNA prime boosted antigen-specific antibody responses to an
average titer of 1/40,000 which is an order of magnitude higher
than the titer predicted to correlate with survival from challenge
with homologous virus, and demonstrates both potency and
durability for this vaccine platform. It is noteworthy that rAd
vectors demonstrated efficient boosting of the antigen-specific
immune response when administered even a year after the final
DNA prime. This result is not altogether surprising since it has
been reported previously that longer prime-boost intervals may
actually enhance immune responses induced by the boosting
immunization [27], possibly because memory cells have had
sufficient time to undergo complete contraction and development
of a central memory phenotype. The strong boosting effect of
rAd5 vectors in DNA primed subjects may also help to overcome
the reduced potency of these vectors when administered to subjects
with pre-existing immunity to the vaccine vector. The ability of
prime-boost vaccination to generate cellular responses in the form
of CD4
+ T-cell help as well as CD8
+ T-cell effector immunity
likely accounts for the protection observed after challenge with
BEBOV, since vaccinated macaques in the present study lacked
antibodies reactive with BEBOV but were fully protected against
disease. Although the anti GP immunoglobulins did not cross-
react with BEBOV, the presence of high-titer antibodies is
indicative of strong underlying antigen-specific immunity induced
by the vaccine, comprising antibody, CD4
+ and CD8
+ T-cell
functions. DNA immunization has been shown to elicit antigen-
specific immunity biased toward the generation of CD4
+ T-cell
memory responses that are necessary for long term memory and
potentiate CD8
+ T-cell functions, while rAd5 vaccine boosting
elicits strong antibody and CD8
+ T-cell responses [28]. The high
magnitude of CD8
+ T-cell activity exhibited here is consistent with
those findings and suggests an important role for this T-cell subset
in the observed protective immunity. It is noteworthy that the
animal with the lowest CD8
+ T-cell response, V4, exhibited a
transient increase in clinical markers of disease. T-cell-mediated
protection from EBOV infection is supported not only by the
robust CD4 and CD8 responses generated by the DNA/rAd
vaccine but also by previous experiments demonstrating that
passive transfer of anti-Ebola neutralizing monoclonal antibody
(KZ52) into naı ¨ve rhesus macaques had no significant effect on
survival when the recipients were exposed to a lethal dose of
ZEBOV [15].
The findings reported herein demonstrate a mechanistic basis
for vaccine-induced immune protection against EBOV infection
and will therefore inform the design of next-generation vaccines.
Furthermore, this study shows that it is possible to protect against
EBOV species whose antigens are not present in the vaccine
formulation. This suggests that current vaccines capable of
eliciting robust T-cell immunity will have the greatest potential




The vaccine vectors used in this study have been described
previously [6]. Replication-defective rAd5 GP vectors were cloned
and purified as described previously [29].
Animal study and safety
Eight 3–5 year old cynomolgus macaques (Macaca fascicularis)
weighing between 2–3 kg were obtained from Covance for this
immunization and challenge study. All animal experiments were
conducted under protocols approved by NIH and USAMRIID
Animal Care and Use committees. All experiments involving the
use of BEBOV in animals were performed in USAMRIID’s BSL-4
laboratory. Research was conducted in compliance with the
Animal Welfare Act and other federal statutes and regulations
relating to animals and experiments involving animals and adheres
to principles stated in the Guide for the Care and Use of Laboratory
Animals, National Research Council, 1996. The facility where this
research was conducted is fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International. Animals were housed individually, and given
enrichment regularly as recommended by the Guide for the Care
and Use of Laboratory Animals (DHEW number NIH 86–23).
Subjects were anesthetized with ketamine prior to blood sampling
or vaccination. The vaccine and control groups each contained
four cynomolgus macaques. After immunization, all the animals
were transferred to the Maximum Containment Laboratory (BSL-
4) at Ft. Detrick, MD for infection with BEBOV, and remained
there through study completion. The monkeys were fed and
checked at least daily according to the protocol.
Macaque immunization and infection
DNA immunizations were administered by Biojector IM
injection, bilateral deltoid, with a mixture of 2 mg each of two
plasmid vectors encoding GP(Z) and GP(S/G). DNA immuniza-
tions were administered at 0, 4, 8, and 14 weeks. Each subject
received a boost with 10
11 particle units (PU) of rAd5 GP(Z) at 12
months following the final DNA priming immunization. All
animals were challenged by the intramuscular route with 1,000
TCID50 of BEBOV, 7 weeks post rAd5 GP boost. The challenge
virus used in this study was isolated from blood specimen
#200706291 from a fatal case infected during the 2007 EBOV
outbreak in Bundibugyo district, Uganda. The virus was isolated
on Vero E6 cells and passaged twice prior to initiating these
experiments.
Blood chemistry
Liver enzyme levels for serum alanine aminotransferase (ALT)
and aspartate aminotransferase (AST) were determined on days 0,
3, 6, 10, 14, 21 and 32 using a Piccolo Point-Of-Care blood
analyzer (Abaxis, Sunnyvale, CA, USA).
Anti-Ebola GP IgG ELISA
Methods for the GP IgG ELISA have been described previously
[5]. Briefly, polyvinyl chloride ELISA plates (Dynatech, Vienna,
VA, or Nunc, Rochester, NY) were coated with Ebola GP,
washed, and incubated with serial dilutions of 1:50-1:50,000 of
subject sera or plasma. Bound IgG was detected using goat anti-
RNA using primers specific for BEBOV. Control and vaccinated animal values are shown in red and blue bars, respectively. Kaplan Meier survival curves
(panel D) were drawn using GraphPad Prism.
doi:10.1371/journal.ppat.1000904.g004
Vaccine-Induced Cross Protection for Ebolavirus
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ed to horseradish peroxidase and Sigma Fast o-phenylenediamine
dihydrochloride (Sigma, St.Louis, MO). The conformation-
dependent antibody, KZ52, is used as a control to ensure native
conformation of the capture antigen, GP. ELISA titers are
expressed as effective concentration 90% (EC90) reciprocal
dilution values, which represent the dilution achieving a 90%
reduction in antigen binding.
T cell intracellular cytokine secretion analysis
Peripheral blood mononuclear cells (PBMC) were isolated from
cynomolgus macaque whole blood samples by separation over
Ficoll, stained, and analyzed by flow cytometry essentially as
described previously [4]. Briefly, PBMC were stimulated with anti-
CD28 and -CD49d antibodies (BD Biosciences), Brefeldin-A
(Sigma-Aldrich, St. Louis, MO), and either dimethylsulfoxide
(DMSO) or a pool of 15-mer peptides overlapping by 11 spanning
the ZEBOV or BEBOV GP open reading frame. Cells were
stained with a mixture of antibodies against lineage markers; CD3-
Cy7-APC, CD4-QD605 (BD Biosciences), CD8-TRPE, and
memory markers CD95 Cy5-PE (BD Biosciences) and CD45RA
QD655, fixed and permeabilized with Cytofix/Cytoperm (BD
Biosciences) followed by intracellular staining with antibodies
against cytokines TNFa-APC, IFNc-Cy7-PE, and IL-2 PE. The
viability dye ViViD (Invitrogen) was included to allow discrimi-
nation between live and dead cells [30]. Samples were acquired on
an LSR II cytometer (BD Biosciences) and analyzed using FlowJo
8.8.5 and SPICE 5.0 software (Tree Star). Cytokine-positive cells
are expressed as a percentage within CD4
+ and CD8
+ T cell
memory subsets after subtraction of non-specific background
responses that were measured in parallel for each sample.
RNA isolation and quantitative real-time RT-PCR (qRT-
PCR)
Total RNA was isolated by mixing in a ratio of 1 to 4.85 plasma
sample to TRI Reagent BD (Sigma). Samples were decontami-
nated with 3% Lysol and then transferred from the high
containment-level laboratory to a BSL3 room. RNAs was
extracted with the RNAqueous kit (Ambion) and tested for
BEBOV by a qRT-PCR assay. Primers and TaqMan probe for
qRT-PCR were designed using the Primer Express software v2.0
(Applied Biosystem, Foster, CA). The primers/probe were:
BEBOV Fw NP 59-TGGAAACCAAGGCGAAACTG-39; BE-
BOV Rv NP 59-ACTTGTGGCATTGGCTTGTCT-39; BE-
BOV Probe 59 FAM-CCACGGGTAGCCCCCAACCAATACA-
BHQ1-39. Samples were prior tested in control PCR runs with
either no RNA template or reverse transcriptase enzyme. One step
qRT-PCRs were performed in triplicate using Iscript One-step
RT-PCR kit (Bio-rad, Hercules, CA) in 25 ml volumes, containing
6 ng total RNA, 12.5 mM each primer, 5 mM probe and 0.25 ml
reference dye BD636 (Megabase, Inc, USA). To make a standard
curve for the absolute quantification, a BEBOV synthetic NP
RNA was generated. The fragment was amplified from a virus
containing -RNA sample with the primers BEBOV Fw NP 59-
AAACGATGGTGGGTATAATA-39 and BEBOV Rv NP 59-
AGCGGGAGGTGCAGTGGCAGGCT-39 and then cloned in
the bidirectional transcriptional vector PCR II-TOPO (Invitrogen,
Carlsbad, CA). Sequence and orientation of the cloned DNA was
confirmed by sequencing reaction. After in vitro transcription using
MAXIscript SP6/T7 Kit (Ambion), the RNA was treated with
DNAse-RNAse free (Ambion), run onto 6%-urea acrylamide gel
and purified by gel-excision followed by elution at 65uC for 4 hrs.
For each run, a standard curve was generated from triplicate
samples of dilution of the purified RNA, ranging from 10
7 to
1610
1 nominal copy equivalent/reaction. Copy number of test
samples was determined by interpolation of the experimentally
determined CT value for the test sample onto the control standard
regression curve. Calculated copy equivalent per reaction values
was then normalized and expressed as copy equivalents per
milliliter of starting plasma. Assay was accepted for r
2 value of the
standard curve being .0.98.
Computational analysis of GP sequences
Multiple alignment of Ebola glycoprotein (GP) sequences (Zaire
1976, GenBank Accession No. NC_002549; Bundibugyo, Acces-
sion No. FJ217161; Sudan 2000, Accession No. NC_006432) was
performed with the program ClustalW2 available at the EBI server
(http://www.ebi.ac.uk/Tools/clustalw2/).
To model the molecular relationship between the glycoprotein
of the vaccine strain (Zaire Mayinga 1976) and of the virus
infecting strain (Bundibugyo 2007), an alignment was generated by
using the program MAFFT [31] and improved manually. The GP
amino acid sequences included in this alignment were Ebola Zaire
Mayinga 1976 (Accession No. Q05320), Zaire Ekron 1976
(Accession No. P87671), Sudan Boniface 1976 (Accession
No. Q66814), Sudan Maleo 1979 (Accession No. Q66798),
Gabon 1994/1997 (Accession No. AAC57989 and O11457),
Sudan Gulu (Accession No. Q7T9D9), Zaire Kikwit 1995
(Accession No. P87666), Reston (Accession No. Q66799), Cote
d’Ivoire (Accession No. Q66810), and Bundibugyo 2007 (Acces-
sion No. ACI28624). A distance-based phylogenetic analysis was
performed using the programs in the PHYLIP 3.68 package [32].
The distance matrix was calculated using the Jones-Taylor-
Thornton (JTT) substitution model [33]. These distances were
clustered with the neighbor-joining (NJ) algorithm [34]. Five
hundred nonparameteric bootstrap replicates were performed to
assess support for individual clades by the data. In the figure the
numbers at the nodes of the tree are the bootstrap percentages,
where any value greater than 0.70 indicates strong support for that
grouping in the data. Branch lengths are measured in substitutions
per site. The multiple sequence alignment was also analyzed using
parsimony with the program PAUP. Five heuristic searches, each
with an independent random starting tree, were performed and a
consensus of the most parsimonious tree or trees from these
searches was calculated. Five hundred nonparametric bootstrap
replicates were performed to assess the support of the trees by the
data. Bootstrap percentages are indicated at the nodes of the tree
and are interpreted as for the distance analysis.
Statistics
Differences in survival outcome were compared by log rank test
using GraphPad Prism 5.0 software. Averaged data values are
presented as mean 6 SEM. Comparison of anti-Ebola GP
antibody titers (EC90) and intracellular cytokine production by T
cell memory subsets were done using one-tailed T-test in
GraphPad software.
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